Literature DB >> 31806388

Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group.

Paula Marincola Smith1, Jordan Baechle2, Carmen C Solórzano1, Marcus Tan1, Alexandra G Lopez-Aguiar3, Mary Dillhoff4, Eliza Beal4, George Poultsides5, John G D Cannon5, Flavio G Rocha6, Angelena Crown6, Clifford Cho7, Megan Beems7, Emily R Winslow8, Victoria R Rendell8, Bradley A Krasnick9, Ryan C Fields9, Shishir K Maithel3, Christina E Bailey1, Kamran Idrees10.   

Abstract

BACKGROUND: Packed red blood cell (PRBC) transfusion has been associated with worse survival in multiple malignancies but its impact on pancreatic neuroendocrine tumors (PNETs) is unknown. The aim of this study was to determine the impact of PRBC transfusion on survival following PNET resection.
METHODS: A retrospective cohort study of PNET patients was performed using the US Neuroendocrine Tumor Study Group database. Demographic and clinical factors were compared. Kaplan-Meier and log-rank analyses were performed. Factors associated with transfusion, overall (OS), recurrence-free (RFS) and progression-free survival (PFS) were assessed by logistic regression.
RESULTS: Of 1129 patients with surgically resected PNETs, 156 (13.8%) received perioperative PRBC transfusion. Transfused patients had higher ASA Class, lower preoperative hemoglobin, larger tumors, more nodal involvement, and increased major complications (all p < 0.010). Transfused patients had worse median OS (116 vs 150 months, p < 0.001), worse RFS (83 vs 128 months, p < 0.01) in curatively resected (n = 1047), and worse PFS (11 vs 24 months, p = 0.110) in non-curatively resected (n = 82) patients. On multivariable analysis, transfusion was associated with worse OS (HR 1.80, p = 0.011) when controlling for TNM stage, tumor grade, final resection status, and pre-operative anemia.
CONCLUSION: PRBC transfusion is associated with worse survival for patients undergoing PNET resection.
Copyright © 2019 International Hepato-Pancreato-Biliary Association Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31806388      PMCID: PMC7263954          DOI: 10.1016/j.hpb.2019.10.2441

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  32 in total

Review 1.  Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.

Authors:  K Oberg; L Kvols; M Caplin; G Delle Fave; W de Herder; G Rindi; P Ruszniewski; E A Woltering; B Wiedenmann
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

2.  AABB Red Blood Cell Transfusion Guidelines: Something for Almost Everyone.

Authors:  Mark H Yazer; Darrell J Triulzi
Journal:  JAMA       Date:  2016-11-15       Impact factor: 56.272

3.  Allogenic Blood Transfusion is Associated with Poor Perioperative and Long-Term Outcome in Esophageal Cancer.

Authors:  Matthias Reeh; Tarik Ghadban; Josephine Dedow; Eik Vettorazzi; Faik G Uzunoglu; Michael Nentwich; Stefan Kluge; Jakob R Izbicki; Yogesh K Vashist
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

4.  Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer.

Authors:  Woo Jin Hyung; Sung Hoon Noh; Dong Woo Shin; JiHunJ Huh; Bong J Huh; Seung Ho Choi; Jin Sik Min
Journal:  Ann Surg Oncol       Date:  2002 Jan-Feb       Impact factor: 5.344

Review 5.  Red blood cell transfusion: a clinical practice guideline from the AABB*.

Authors:  Jeffrey L Carson; Brenda J Grossman; Steven Kleinman; Alan T Tinmouth; Marisa B Marques; Mark K Fung; John B Holcomb; Orieji Illoh; Lewis J Kaplan; Louis M Katz; Sunil V Rao; John D Roback; Aryeh Shander; Aaron A R Tobian; Robert Weinstein; Lisa Grace Swinton McLaughlin; Benjamin Djulbegovic
Journal:  Ann Intern Med       Date:  2012-07-03       Impact factor: 25.391

Review 6.  Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis.

Authors:  Chang Sun; Yi Wang; Hou Shan Yao; Zhi Qian Hu
Journal:  Int J Surg       Date:  2014-12-06       Impact factor: 6.071

7.  Expression of HLA class I/II antigens and T cell immune response in human neuroendocrine tumors of the pancreas.

Authors:  E Ryschich; F Autschbach; S Eisold; E Klar; M W Buchler; J Schmidt
Journal:  Tissue Antigens       Date:  2003-07

8.  The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy.

Authors:  Brian J Linder; Igor Frank; John C Cheville; Matthew K Tollefson; R Houston Thompson; Robert F Tarrell; Prabin Thapa; Stephen A Boorjian
Journal:  Eur Urol       Date:  2013-01-11       Impact factor: 20.096

Review 9.  Current understanding of the molecular biology of pancreatic neuroendocrine tumors.

Authors:  Jianliang Zhang; Rony Francois; Renuka Iyer; Mukund Seshadri; Maria Zajac-Kaye; Steven N Hochwald
Journal:  J Natl Cancer Inst       Date:  2013-07-09       Impact factor: 13.506

10.  Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  Nick M Spirtos; Cynthia M Westby; Hervy E Averette; John T Soper
Journal:  Am J Clin Oncol       Date:  2002-08       Impact factor: 2.339

View more
  1 in total

1.  A novel difficulty scoring system of laparoscopic liver resection for liver tumor.

Authors:  Cheng Xi; Maoqun Zhu; Tianhao Ji; Yulin Tan; Lin Zhuang; Zhiping Yuan; Zheng Zhang; Litian Xu; Zhilin Liu; Xuezhong Xu; Wenbo Xue; Wei Ding
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.